** Insmed's INSM.O shares down 1% after hours at $96.88 as biopharma co plans equity raise
** Bridgewater, New Jersey-based Insmed announces $650 mln stock offering
** Goldman Sachs and Leerink are jt bookrunners
** On Tues, INSM shares soared 29% after co said its inhaled drug, treprostinil palmitil, reduced blood pressure in the lungs and improved exercise capacity in patients in mid-stage study
** The shares added another 7.8% to close at $97.98 on Weds, a more than two-decade high
** Co plans to use net offering proceeds for continued R&D and development of its product candidates, per the SEC filing
** With ~182 mln shares outstanding, INSM has nearly $18 bln market cap
** Through Weds close, stock up 42% YTD
** All 19 analysts are bullish on INSM including 6 "strong buy" ratings; median PT of $110 up from $97 a month ago, latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.